-
公开(公告)号:US10058091B2
公开(公告)日:2018-08-28
申请号:US15459813
申请日:2017-03-15
发明人: Michael Wolf , Jancarlo Sarita , Jeffrey Karl Sutton , Rafael Cordero , Michael Zocchi , Philip Keegan , Narendran Renganathan , Robert Harhen
CPC分类号: A01N1/0263 , A01N1/021 , A61J1/10 , A61J1/1468 , A61K35/00 , A61M1/0272 , A61M2202/0208 , C12M23/14
摘要: The present disclosure relates to Oxygen Reduction Disposable kits (ORDKit), devices and methods for the improved preservation of whole blood and blood components. The improved devices and methods for the collection of blood and blood components provide for whole blood and blood components having reduced levels of oxygen. The devices and methods provide for the rapid preparation of deoxygenated blood and blood components for storage that improves the overall quality of the transfused blood and improves health outcomes in patients.
-
62.
公开(公告)号:US10023649B2
公开(公告)日:2018-07-17
申请号:US15312515
申请日:2015-05-15
发明人: Chia-Yang Lin , Shihao Chen , LiFen Lee , Shobha Potluri , Denis Healy , Margaret Marshall , Naoki Sawada
摘要: The present disclosure describes combination therapies comprising an antibody which specifically binds to human CCR4 and a selective 4-1BB agonist, and the use of the combination therapies for the treatment of cancer.
-
公开(公告)号:US10022406B2
公开(公告)日:2018-07-17
申请号:US15093679
申请日:2016-04-07
发明人: Thomas Julius Borody
IPC分类号: A61K35/74 , A61K35/24 , A61K9/48 , C12N1/00 , A61M5/142 , A61K35/742 , A61P1/12 , A61K35/00 , A61M31/00
摘要: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual, e.g., a human or an animal. The invention also provides devices for delivering a fecal material to a patient.
-
公开(公告)号:US09980673B2
公开(公告)日:2018-05-29
申请号:US15058964
申请日:2016-03-02
发明人: Majid Sarrafzadeh , William Kaiser , Alireza Mehrnia , Barbara M. Bates-Jensen , Frank Wang , Michael Flesch , Joseph Boystak , Yeung Lam
CPC分类号: A61B5/447 , A61B5/05 , A61B5/0533 , A61B5/0537 , A61B5/443 , A61B5/445 , A61B5/6843 , A61B5/6844 , A61B5/7271 , A61B5/7285 , A61B2562/0214 , A61B2562/0247 , A61B2562/04 , A61B2562/046 , A61B2562/066 , A61B2562/164
摘要: A handheld, conforming capacitive sensing apparatus configured to measure Sub-Epidermal Moisture (SEM) as a mean to detect and monitor the formation of pressure ulcers. The device incorporates an array of electrodes which are excited to measure and scan SEM in a programmable and multiplexed manner by a battery-less RF-powered chip. The scanning operation is initiated by an interrogator which excites a coil embedded in the apparatus and provides the needed energy burst to support the scanning/reading operation. Each electrode measures the equivalent sub-epidermal capacitance corresponding and representing the moisture content.
-
公开(公告)号:US09856485B2
公开(公告)日:2018-01-02
申请号:US14337932
申请日:2014-07-22
CPC分类号: C12N15/8213 , C12N15/63 , C12N15/8217 , C12N15/8218 , C12N15/8243
摘要: Recombinant DNA constructs, for use in plants and plant cells, have site-specific recombination sites that allow assessing phenotypes and modes of action by over expression or suppression of endogenous genes. In an aspect, a single DNA construct can be switched between over expression and suppression by the action of a recombinase such as the Cre recombinase on constructs having lox recombination sites. Other useful recombination systems include the Flp/frt system, the R/Rs system, the Dre/rox system, and the GIN/gix system.
-
公开(公告)号:US09801784B2
公开(公告)日:2017-10-31
申请号:US15475898
申请日:2017-03-31
发明人: Tatsuro Yoshida , Rafael Cordero , Jancarlo Sarita , Michael Zocchi , Michael Wolf , Philip Michael Keegan , Narendran Renganathan , Jeffrey Karl Sutton
CPC分类号: A61J1/10 , A01N1/0263 , A61J1/1462 , A61J1/1468 , A61J1/1475 , A61J1/1487 , A61J1/18 , A61M1/0209 , B32B1/02 , B32B3/06 , B32B3/08 , B32B7/12 , B32B27/08 , B32B27/18 , B32B27/205 , B32B27/286 , B32B27/306 , B32B27/32 , B32B27/34 , B32B27/36 , B32B2250/24 , B32B2307/308 , B32B2307/412 , B32B2307/414 , B32B2307/514 , B32B2307/7242 , B32B2307/7244 , B32B2307/7246 , B32B2307/7265 , B32B2439/80 , B32B2535/00 , B65D81/266 , B65D81/268
摘要: A blood storage container for the anaerobic storage of blood, having enhanced sealing methods and materials for the preservation of stored blood is provided.
-
公开(公告)号:USD795126S1
公开(公告)日:2017-08-22
申请号:US29550845
申请日:2016-01-07
申请人: David Yurman IP LLC
设计人: David Yurman , Evan Yurman
-
公开(公告)号:US09713334B2
公开(公告)日:2017-07-25
申请号:US15015957
申请日:2016-02-04
发明人: James A. Baum , Artem G. Evdokimov , Farhad Moshiri , Timothy J. Rydel , Eric J. Sturman , Moritz von Rechenberg , Halong Vu , Andrew M. Wollacott , Meiying Zheng
IPC分类号: C12N9/00 , A01N63/02 , C12N15/82 , C07K14/00 , C07K14/325 , A01N37/46 , C07K14/435 , C07K14/32
CPC分类号: A01N63/02 , A01N37/46 , C07K14/001 , C07K14/32 , C07K14/325 , C07K14/43577 , C12N15/8286 , Y02A40/162
摘要: The present invention discloses Hemipteran insect inhibitory proteins, methods of using such proteins, nucleotide sequences encoding such proteins, methods of detecting and isolating such proteins, and their use in agricultural systems.
-
公开(公告)号:US09675707B2
公开(公告)日:2017-06-13
申请号:US14789873
申请日:2015-07-01
申请人: GENENTECH, INC.
发明人: Wei-Ching Liang , Chie Sakanaka , Yan Wu
CPC分类号: A61K47/48638 , A61K47/6811 , A61K47/6851 , A61K47/6889 , A61K51/1045 , A61K2039/505 , C07K16/005 , C07K16/30 , C07K16/3069 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/92 , C12N9/96
摘要: Anti-TAT226 antibodies and immunoconjugates thereof are provided. Methods of using anti-TAT226 antibodies and immunoconjugates thereof are provided.
-
公开(公告)号:US09572841B2
公开(公告)日:2017-02-21
申请号:US15017372
申请日:2016-02-05
申请人: Crestovo LLC
发明人: Thomas Julius Borody
IPC分类号: A61K39/00 , A61K39/38 , A61K39/02 , A61K39/08 , A61K39/108 , A61K35/741 , A61K35/74 , A61K38/48 , A61K35/742 , A61K35/744 , A61K35/747 , A61K36/062 , A61K45/06 , A61K38/14 , A61K31/341 , A61K31/41 , A61K31/495 , A61K31/7034 , A23L2/52 , A61K35/745 , A61K35/38 , A61K35/24 , A61K9/00 , A23C9/123 , A61K9/48 , A23C9/13 , A23C9/127 , A61K31/545 , A61K35/76 , A61K31/43 , A61K38/00 , A61K31/7048 , A61K9/50 , A61K39/39 , A61K51/12 , A61K35/00
CPC分类号: A61K35/742 , A23C9/123 , A23C9/127 , A23C9/13 , A23L2/52 , A23L33/135 , A23V2002/00 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K9/48 , A61K9/4891 , A61K9/50 , A61K9/5005 , A61K9/5078 , A61K31/341 , A61K31/41 , A61K31/43 , A61K31/495 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K35/24 , A61K35/37 , A61K35/38 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/062 , A61K38/00 , A61K38/14 , A61K38/4893 , A61K39/00 , A61K39/39 , A61K45/06 , A61K51/1217 , A61K2035/115 , C12N2795/00032 , Y02A50/401 , Y02A50/469 , Y02A50/473 , A61K2300/00
摘要: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
-
-
-
-
-
-
-
-
-